What does CUSIP 22663K107 represent in this 13F holders report?

CUSIP 22663K107 is the security identifier for CRNX - CRINETICS PHARMACEUTICALS IN - COMMON STOCK used to aggregate holder disclosures.

How many institutions held CRNX - CRINETICS PHARMACEUTICALS IN - COMMON STOCK in Q2 2020?

79 institutional investors reported CRNX - CRINETICS PHARMACEUTICALS IN - COMMON STOCK for Q2 2020. Use the holders table for investor-level position and value details.

CRINETICS PHARMACEUTICALS IN - COMMON STOCK (CRNX)

CUSIP: 22663K107

Q2 2020 13F Holders as of 30 Jun 2020

Type / Class: Equity / COMMON STOCK
Shares outstanding: 105,000,216
Total 13F shares: 31,451,376
Share change: +10,773,756
Total reported value: $546,085,663
Price per share: $17.52
Number of holders: 79
Value change: +$188,712,886
Number of buys: 68
Number of sells: 10

Quarterly Holders Quick Answers

What is CUSIP 22663K107?
CUSIP 22663K107 identifies CRNX - CRINETICS PHARMACEUTICALS IN - COMMON STOCK in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q3 2020
Previous quarter: Q1 2020

Recent filing periods for CUSIP 22663K107:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of CRNX - CRINETICS PHARMACEUTICALS IN - COMMON STOCK (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
FMR LLC	13F	Company	3.3%	3,438,300	$50,543,000	—	31 Mar 2020	13F
Vivo Capital, LLC	13F	Company	3.2%	3,320,801	$48,816,000	—	31 Mar 2020	13F
PERCEPTIVE ADVISORS LLC	13F	Company	2.5%	2,587,953	$38,042,000	—	31 Mar 2020	13F
ORBIMED ADVISORS LLC	13F	Company	1.9%	2,039,282	$29,977,000	—	31 Mar 2020	13F
RA CAPITAL MANAGEMENT, L.P.	13F	Company	1.9%	1,961,209	$28,830,000	—	31 Mar 2020	13F
5AM Venture Management, LLC	13F	Company	1.8%	1,862,286	$27,376,000	—	31 Mar 2020	13F
EVENTIDE ASSET MANAGEMENT, LLC	13F	Company	0.9%	947,000	$13,921,000	—	31 Mar 2020	13F
BlackRock Finance, Inc.	13F	Company	0.69%	722,303	$10,617,000	—	31 Mar 2020	13F
VANGUARD GROUP INC	13F	Company	0.48%	508,217	$7,471,000	—	31 Mar 2020	13F
JANUS HENDERSON GROUP PLC	13F	Company	0.47%	491,691	$7,228,000	—	31 Mar 2020	13F
Opaleye Management Inc.	13F	Company	0.35%	368,750	$5,421,000	—	31 Mar 2020	13F
EcoR1 Capital, LLC	13F	Company	0.33%	350,000	$5,145,000	—	31 Mar 2020	13F
Burrage Capital Management LLC	13F	Company	0.27%	282,272	$4,022,000	—	31 Mar 2020	13F
STATE STREET CORP	13F	Company	0.21%	224,494	$3,300,000	—	31 Mar 2020	13F
Polar Capital LLP	13F	Company	0.19%	200,000	$2,940,000	—	31 Mar 2020	13F
VICTORY CAPITAL MANAGEMENT INC	13F	Company	0.18%	184,724	$2,715,000	—	31 Mar 2020	13F
BAKER BROS. ADVISORS LP	13F	Company	0.17%	175,000	$2,573,000	—	31 Mar 2020	13F
Novo Holdings A/S	13F	Company	0.16%	164,453	$2,417,000	—	31 Mar 2020	13F
NORTHERN TRUST CORP	13F	Company	0.15%	162,345	$2,387,000	—	31 Mar 2020	13F
New Leaf Venture Partners, L.L.C.	13F	Company	0.13%	141,000	$2,073,000	—	31 Mar 2020	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.13%	134,019	$1,970,000	—	31 Mar 2020	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.05%	52,722	$776,000	—	31 Mar 2020	13F
ALPS ADVISORS INC	13F	Company	0.04%	44,040	$647,000	—	31 Mar 2020	13F
Bank of New York Mellon Corp	13F	Company	0.03%	36,032	$529,000	—	31 Mar 2020	13F
CITADEL ADVISORS LLC	13F	Company	0.03%	35,737	$526,000	—	31 Mar 2020	13F
PRICE T ROWE ASSOCIATES INC /MD/	13F	Company	0.03%	28,408	$418,000	—	31 Mar 2020	13F
Nuveen Asset Management, LLC	13F	Company	0.03%	28,050	$413,000	—	31 Mar 2020	13F
CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM	13F	Company	0.02%	19,100	$281,000	—	31 Mar 2020	13F
Swiss National Bank	13F	Company	0.02%	18,800	$276,000	—	31 Mar 2020	13F
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	13F	Company	0.02%	17,197	$253,000	—	31 Mar 2020	13F
STATE OF WISCONSIN INVESTMENT BOARD	13F	Company	0.02%	17,100	$251,000	—	31 Mar 2020	13F
ALLIANCEBERNSTEIN L.P.	13F	Company	0.01%	14,800	$218,000	—	31 Mar 2020	13F
NEW YORK STATE COMMON RETIREMENT FUND	13F	Company	0.01%	12,700	$187,000	—	31 Mar 2020	13F
RHUMBLINE ADVISERS	13F	Company	0.01%	12,698	$187,000	—	31 Mar 2020	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.01%	9,436	$139,000	—	31 Mar 2020	13F
UBS Group AG	13F	Company	0.01%	8,216	$121,000	—	31 Mar 2020	13F
WELLS FARGO & COMPANY/MN	13F	Company	0.01%	6,759	$99,000	—	31 Mar 2020	13F
AMERICAN INTERNATIONAL GROUP, INC.	13F	Company	0.01%	6,537	$96,000	—	31 Mar 2020	13F
MetLife Investment Management, LLC	13F	Company	0.01%	5,835	$85,775	—	31 Mar 2020	13F
MARSHALL WACE, LLP	13F	Company	0%	4,246	$62,000	—	31 Mar 2020	13F
METROPOLITAN LIFE INSURANCE CO/NY	13F	Company	0%	4,173	$61,343	—	31 Mar 2020	13F
DEUTSCHE BANK AG\	13F	Company	0%	3,798	$56,000	—	31 Mar 2020	13F
BARCLAYS PLC	13F	Company	0%	3,660	$54,000	—	31 Mar 2020	13F
JPMORGAN CHASE & CO	13F	Company	0%	3,623	$53,000	—	31 Mar 2020	13F
BNP PARIBAS FINANCIAL MARKETS	13F	Company	0%	3,447	$50,671	—	31 Mar 2020	13F
CITIGROUP INC	13F	Company	0%	3,217	$47,000	—	31 Mar 2020	13F
Jacobi Capital Management LLC	13F	Company	0%	3,000	$44,000	—	31 Mar 2020	13F
HERSHEY TRUST CO	13F	Company	0%	2,895	$43,000	—	31 Mar 2020	13F
MORGAN STANLEY	13F	Company	0%	2,251	$34,000	—	31 Mar 2020	13F
Legal & General Group Plc	13F	Company	0%	1,872	$28,000	—	31 Mar 2020	13F

Institutional Holders of CRINETICS PHARMACEUTICALS IN - COMMON STOCK (CRNX) as of Q2 2020

As of 30 Jun 2020, CRINETICS PHARMACEUTICALS IN - COMMON STOCK (CRNX) was held by 79 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 31,451,376 shares. The largest 10 holders included FMR LLC, PERCEPTIVE ADVISORS LLC, ORBIMED ADVISORS LLC, RA CAPITAL MANAGEMENT, L.P., Vivo Capital, LLC, Versant Venture Management, LLC, BlackRock Inc., 5AM Venture Management, LLC, EVENTIDE ASSET MANAGEMENT, LLC, and VANGUARD GROUP INC. This page lists 79 institutional shareholders reporting positions in this security for the Q2 2020 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q2 2020 vs Q1 2020 Across Filers

Q1 2020 holders

Q2 2020 holders

Holder diff

Investor	Q1 2020 Shares	Q2 2020 Shares	Share Diff	Share Chg %	Q1 2020 Value $	Q2 2020 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.